{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:32:48Z","timestamp":1774639968450,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006428","name":"Bureau for Economic Growth, Education, and Environment, United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jvacx.2020.100070","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T21:33:00Z","timestamp":1595971980000},"page":"100070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Safety and immunogenicity of the Rift Valley fever arMP-12 \u0394NSm21\/384 candidate vaccine in pregnant ewes"],"prefix":"10.1016","volume":"6","author":[{"given":"Z.","family":"Boumart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Bamouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Safini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.O.","family":"Tadlaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Elharrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2020.100070_b0005","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV virus taxonomy profile: pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jvacx.2020.100070_b0010","unstructured":"ICTV Virus Taxonomy. Genus: Pegivirus \u2013 Flaviviridae \u2013 Positive-sense RNA Viruses \u2013 International Committee on Taxonomy of Viruses (ICTV). 10th Rep Int Comm Taxon Viruses; 2017."},{"key":"10.1016\/j.jvacx.2020.100070_b0015","doi-asserted-by":"crossref","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010","journal-title":"Vet Res"},{"key":"10.1016\/j.jvacx.2020.100070_b0020","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","article-title":"Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves","volume":"29","author":"Von Teichman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0025","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2020.100070_b0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.jvacx.2020.100070_b0040","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jvacx.2020.100070_b0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0050","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100070_b0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100070_b0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100070_b0065","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0075","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100070_b0080","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.vaccine.2013.12.064","article-title":"Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep","volume":"32","author":"Weingartl","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0090","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0095","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.vaccine.2019.01.067","article-title":"Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12\u0394NSm21\/384 vaccine candidate for sheep, goats and calves","volume":"37","author":"Boumart","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100070_b0100","unstructured":"European Pharmacopeia OIE 2008 n.d.;1.1."},{"key":"10.1016\/j.jvacx.2020.100070_b0105","unstructured":"Authenticated U.S government information; animal and plant health inspection service, USDA n.d. n.d.;113:701\u20132."},{"key":"10.1016\/j.jvacx.2020.100070_b0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jvacx.2020.100070_b0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4269\/ajtmh.2010.09-0288","article-title":"An investigation of a major outbreak of rift valley fever in Kenya: 2006\u20132007","volume":"83","author":"Nguku","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2020.100070_b0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/vbz.2009.0205","article-title":"Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates","volume":"10","author":"Busquets","year":"2010","journal-title":"Vector-Borne Zoonotic Dis"},{"key":"10.1016\/j.jvacx.2020.100070_b0125","first-page":"119","article-title":"Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents","volume":"44","author":"Coetzer","year":"1977","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100070_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007898","article-title":"Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas","volume":"14","author":"Oymans","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2020.100070_b0135","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2020.100070_b0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0034-5288(92)90029-2","article-title":"Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine","volume":"52","author":"Baskerville","year":"1992","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.jvacx.2020.100070_b0145","unstructured":"Coetzer JAW, Thomson GR, Tustin RC. Infectious diseases of livestock with special reference to Southern Africa. In: Coetzer JAW, Thomson GR, R.C. Tustin. Cape T. Oxford Univ. Press; 1994. p. 1539\u201348."}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:04:07Z","timestamp":1762913047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136220300176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"alternative-id":["S2590136220300176"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100070","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the Rift Valley fever arMP-12 \u0394NSm21\/384 candidate vaccine in pregnant ewes","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100070"}}